

Policy: MP233

Section: Medical Benefit Policy

Subject: Autologous Injectable Platelet and Blood Products

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Autologous Injectable Platelet and Blood Products

II. Purpose/Objective:

To provide a policy of coverage regarding Autologous Injectable Platelet and Blood Products

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.

- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION: Autologous platelet-derived growth factors (APDGF), also referred to as platelet gel or platelet-rich plasma, have been proposed for use in the treatment of surgical and chronic wounds (e.g., lower extremity wounds), tendonitis, joint capsular injuries, soft tissue trauma (e.g., tendon and ligament ruptures), and muscle injuries and disorders. Bone marrow-derived mesenchymal stem cells have been proposed as a regenerative treatment for injuries to cartilage and bones.

FOR MEDICARE and MEDICAID BUSINESS SEGMENT:

The Centers for Medicare & Medicaid Services (CMS) will cover autologous PRP for the treatment of chronic non-healing diabetic wounds under section 1862(a)(1)(A) of the Social Security Act for a duration of 20 weeks, when prepared by devices whose Food and Drug Administration-cleared indications include the management of exuding cutaneous wounds, such as diabetic ulcers.

Coverage of autologous PRP for the treatment of all other chronic non-healing wounds will be determined by the local MACs under section 1862(a)(1)(A) of the Act.

EXCLUSIONS:

The Plan does **NOT** provide coverage for Autologous Platelet-Derived Growth Factor for any indication including but not limited to surgical wounds, chronic non-healing wounds, Epicondylitis, Plantar Fasciitis, Dupuytren's Contracture, bone healing and fusion, tendinopathy and sinus surgery because it is considered **experimental, investigational or unproven**. The Geisinger Technology Assessment Committee evaluated this technology and concluded that there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established other tests or technologies.

The Plan does **NOT** provide coverage for bone marrow plasma or bone marrow-derived mesenchymal stem cell injection for any orthopedic condition because it is considered experimental, investigational or unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established other tests or technologies.

The Plan does **NOT** provide coverage for autologous platelet gel following total knee arthroplasty or for treatment of diabetic foot ulcer because it is considered experimental, investigational or unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established other tests or technologies.

The Plan does **NOT** provide coverage for platelet-rich fibrin for intra-bony defects in chronic periodontitis and rotator cuff tears because it is considered experimental, investigational or unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established other tests or technologies.

The Plan does **NOT** provide coverage for adipose-tissue-derived stem cells injection (Habeo cell therapy) for the treatment of scleroderma (systemic sclerosis) or any other indications because it is considered experimental, investigational or unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this technology on health outcomes when compared to established other tests or technologies.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Autologous Platelet-Derived Growth Factor

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider

reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

- P9020 Platelet rich plasma, each unit
- S9055 Procuren or other growth factor preparation to promote wound healing
- 0232T Injection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
- 0481T Injection(s) autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation when performed)
- 0489T Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells
- 0490T multiple injections in one or both hands
- G0460 Autologous platelet rich plasma for non-diabetic chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment
- 0565T AUTOLOGOUS CELLULAR IMPLANT DERIVED FROM ADIPOSE TISSUE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEES; TISSUE HARVESTING AND CELLULAR IMPLANT CREATION
- 0566T AUTOLOGOUS CELLULAR IMPLANT DERIVED FROM ADIPOSE TISSUE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEES; INJECTION OF CELLULAR IMPLANT INTO KNEE JOINT INCLUDING ULTRASOUND GUIDANCE, UNILATERAL
- P9099 BLOOD COMPONENT OR PRODUCT NOT OTHERWISE CLASSIFIED

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Triage Committee. Platelet Rich Plasma Gel Injection (PRP). June 2009.

Anzarut A, Guenther CR, Edwards DC, Tsuyuki RT. Completely autologous platelet gel in breast reduction surgery: a blinded, randomized, controlled trial. *Plast Reconstr Surg*. 2007 Apr 1;119(4):1159-66. PMID 17496586

Driver VR, Hanft J, Fylling CP, Beriou JM, AutoloGel™ Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. *Ostomy Wound Manage*. 2006 Jun;52(6):68-70, 72, 74 passim. PMID 16799184

Feiz-Erfan I, Harrigan M, Sonntag VKH, Harrington TR. Effect of autologous platelet gel on early and late graft fusion in anterior cervical spine surgery. *J Neurosurg Spine*. 2007 Nov;7(5):496-502. PMID 17977190

Kazakos K, Lyras DN, Verettas D, Tilkeridis K, Tryfonidis M. The use of autologous PRP gel as an aid in the management of acute trauma wounds. *Injury*. 2008 Aug 12 [Epub ahead of print] PMID 18703188

Zavadil DP, Satterlee CC, Costigan JM, Holt DW, Shostrom VK. Autologous platelet gel and platelet-poor plasma reduce pain with total shoulder arthroplasty. *J Extra Corpor Technol*. 2007 Sep;39(3):177-82. PMID 17972452

Everts PA, Jakimowicz JJ, van Beek M, Schönberger JP, Devilee RJ, Overdevest EP, Knape JT, van Zundert A. Reviewing the structural features of autologous platelet-leukocyte gel and suggestions for use in surgery. *Eur Surg Res*. 2007;39(4):199-207. Epub 2007 Apr 13.

Mishra A, Woodall, J Jr., Vierira A. Treatment of tendon and muscle using platelet-rich plasma. *Clin Sports Med* - Jan, 2009; 28(1); 113-125.

SafeBlood Technologies Inc. Autologous platelet grafting™ [product information]. Updated 2001. Accessed Apr 9, 2009. Available at URL address: <http://www.safebloodtech.com/platelet.asp>

Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. *Curr Rev Musculoskelet Med* Epub 2008.

Robert J. de Vos, MD; Adam Weir, MBBS; Hans T. M. van Schie, DVM, PhD; Sita M. A. Bierma-Zeinstra, PhD; Jan A. N. Verhaar, MD, PhD; Harrie Weinans, PhD; Johannes L. Tol, MD, PhD Platelet-Rich Plasma Injection for Chronic Achilles Tendinopathy *JAMA*. 2010;303(2):144-149

Marquez De Aracena Del Cid R, Montero De Espinosa Escoriaza I. Subconjunctival application of regenerative factor-rich plasma for the treatment of ocular alkali burns. *Eur J Ophthalmol*. 2009 Nov-Dec;19(6):909-15.

Spyridakis M, Christodoulidis G, Chatzitheofilou C, et al. The role of the platelet-rich plasma in accelerating the wound-healing process and recovery in patients being operated for pilonidal sinus disease: preliminary results. *World J Surg*. 2009 Aug;33(8):1764-9.

Hayes Inc. Directory. Autologous Platelet Concentrate for Wound Treatment. November 2007. Updated November 2009. Updated Dec. 2022

ECRI. Platelet-derived Growth Factors for Treating Chronic, Nonhealing Wounds. Health Technology Assessment Service. Plymouth Meeting (PA): ECRI Institute; 2012 March 20. [Hotline Service].

ECRI. Growth Factors for Treating Chronic Plantar Fasciitis. Health Technology Assessment Service. Plymouth Meeting (PA): ECRI Institute; 2012 March 20. [Hotline Service].

Agency for Healthcare Research and Quality (AHRQ). Treatment of Pressure Ulcers.1994. Available at: <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.chapter.5124>. Accessed June 2010.

Centers for Medicare and Medicaid Services. MLM Matters MM8213 <http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM8213.pdf>

Lee, KS. Platelet-rich plasma injection. *Semin Musculoskelet Radiol*. 2013; 17(1): 91-8.

Jiang, D., Wang, JH. Tendinopathy and its treatment with platelet-rich plasma (PRP). *Histol Histopathol*. 2013; 28(12): 1537-1546

Stanco, D., Vigano, M., Croiset-SJ., De Girolamo, L. Applications and limits of platelet-rich plasma in sports related injuries. *J Biol Homeost Agents*. 2012; 26(2 Suppl 1): 53S-61S.

Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev*. 2012 Oct 17;10:CD006899. doi: 10.1002/14651858.CD006899

de Almeida, AM, Demange, MK, Sobrado, MF, Rodrigues, MB, Pedrinelli, A, Hernandez, AJ. Patellar tendon healing with platelet-rich plasma: a prospective randomized controlled trial. *Am J Sports Med*. 2012 Jun;40(6):1282-8.

Malavolta, EA, Gracitelli, ME, Ferreira Neto, AA, Assuncao, JH, Bordalo-Rodrigues, M, de Camargo, OP. Platelet-rich plasma in rotator cuff repair: a prospective randomized study. *Am J Sports Med*. 2014 Oct;42(10):2446-54.

Zhao, JG, Zhao, L, Jiang, YX, Wang, ZL, Wang, J, Zhang, P. Platelet-Rich Plasma in Arthroscopic Rotator Cuff Repair: A Meta-Analysis of Randomized Controlled Trials. *Arthroscopy*. 2014 Sep 30.

Jo, CH, Shin, JS, Lee, YG, et al. Platelet-rich plasma for arthroscopic repair of large to massive rotator cuff tears: a randomized, single-blind, parallel-group trial. *Am J Sports Med*. 2013 Oct;41(10):2240-8.

Ruiz-Moneo, P, Molano-Munoz, J, Prieto, E, Algorta, J. Plasma rich in growth factors in arthroscopic rotator cuff repair: a randomized, double-blind, controlled clinical trial. *Arthroscopy*. 2013 Jan;29(1):2-9.

Weber, SC, Kauffman, JI, Parise, C, Weber, SJ, Katz, SD. Platelet-rich fibrin matrix in the management of arthroscopic repair of the rotator cuff: a prospective, randomized, double-blinded study. *Am J Sports Med*. 2013 Feb;41(2):263-70.

Chang, KV, Hung, CY, Aliwarga, F, Wang, TG, Han, DS, Chen, WS. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. *Arch Phys Med Rehabil.* 2014 Mar;95(3):562-75.

de Vos, RJ, Windt, J, Weir, A. Strong evidence against platelet-rich plasma injections for chronic lateral epicondylar tendinopathy: a systematic review. *Br J Sports Med.* 2014 Jun;48(12):952-6.

Figuroa D, Figuroa F, Calvo R, et al. Platelet-Rich Plasma Use in Anterior Cruciate Ligament Surgery: Systematic Review of the Literature. *Arthroscopy.* Jan 14 2015.

Franceschi F, Papalia R, Franceschetti E, et al. Platelet-rich plasma injections for chronic plantar fasciopathy: a systematic review. *Br Med Bull.* Dec 2014;112(1):83-95.

de Vos RJ, Windt J, Weir A. Strong evidence against platelet-rich plasma injections for chronic lateral epicondylar tendinopathy: a systematic review. *Br J Sports Med.* Feb 21 2014.

Beitzel K, Allen D, Apostolakos J, et al. US Definitions, Current Use, and FDA stance on the use of Platelet-rich Plasma in Sports Medicine. *J Knee Surg* 2015 Feb;28(1):29-34.

Pak J, Lee JH, Lee SH. A novel biological approach to treat chondromalacia patellae. *PLoS One.* 2013;8(5):e64569

van Ark M, Zwerver J, van den Akker-Scheek I. Injection treatments for patellar tendinopathy. *Br J Sports Med.* 2011;45(13):1068-1076

Lau RL, Perruccio AV, Evans HM, et al. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review. *BMC Musculoskelet Disord.* 2014; 15:156.

Vangsness CT, Farr J, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medical meniscectomy: a randomized, double-blind, controlled study. *J Bone Joint Surg Am.* 2014; 96(2): 90-98

Gupta PK, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. *Stem Cell Res Ther.* 2012;3(4):25

Wong KL, Lee KB, Tai BC, et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up. *Arthroscopy.* 2013; 39(12):2020-2028

Wakitani S, Nawata, et al., Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. *J Tissue Eng Regen Med* 2007; 1(1):74-9.

Centeno CJ, Schultz JR, et al., Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique, *Current Stem Cell Research and Therapy*, 2010 (5)

Filardo G, Madry H, Jelic M, et al. Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. *Knee Surg Sports Traumatol Arthrosc.* 2013; 21(8):1717-1729.

Vizcaíno G. Orthobiologic treatment with platelet-rich plasma: Is there sufficient evidence for its recommendation? *Invest Clin.* 2016;57(1):1-2.

Martinez-Zapata MJ, Martí-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev.* 2016;(5):CD006899.

Knop E, Paula LE, Fuller R. Platelet-rich plasma for osteoarthritis treatment. *Rev Bras Reumatol Engl Ed.* 2016;56(2):152-164.

Daumas A, Magalon J, Jouve E, et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. *Curr Res Transl Med.* 2017;65(1):40-43

Guillaume-Jugnot P, Daumas A, Magalon J, et al. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. *Rheumatology* 2016;55(2):301-306.

Miron RJ, Fujioka-Kobayashi M, Bishara M et al. Platelet-rich fibrin and soft tissue wound healing: A systematic review. *Tissue Eng Part B Rev*. 2017 Feb;23(1):83-99.

Escamilla Cardenosa, M, Dominguez-Maldonado, G, Cordoba-Fernandez, A. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. *Journal of Tissue Viability*. 2017 May;26(2):138-43.

Wang Y, Han C, Hao J, et al. Efficacy of platelet-rich plasma injections for treating Achilles tendonitis: Systematic review of high-quality randomized controlled trials. *Orthopade*. 2019;48(9):784-791.

Hurley ET, Hannon CP, Pauzenberger L, et al. Nonoperative treatment of rotator cuff disease with platelet-rich plasma: A systematic review of randomized controlled trials. *Arthroscopy*. 2019;35(5):1584-1591.

Rahimzadeh P, Imani F, Faiz SHR, Entezary SR, Zamanabadi MN, Alebouyeh MR. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. *Clin Interv Aging*. 2018 Jan 4;13:73-79.

Liu CJ, Yu KL, Bai JB, et al. Platelet-rich plasma injection for the treatment of chronic Achilles tendinopathy: A meta-analysis. *Medicine (Baltimore)*. 2019;98(16):e15278.

Di Martino A, Di Matteo B, Papio T, et al. Platelet-rich plasma versus hyaluronic acid injections for the treatment of knee osteoarthritis: Results at 5 years of a double-blind, randomized controlled trial. *Am J Sports Med*. 2018 Dec;46(13):3635-46518814532.

Hayes, Inc., Medical Technology Directory. Platelet-Rich Plasma for Treatment of Conditions of the Achilles Tendon and Plantar Fascia. Hayes, Inc.; June 1, 2020.

Hayes, Inc., Medical Technology Directory. Comparative Effectiveness Review of Platelet-Rich Plasma for Rotator Cuff Repairs, Tendinopathies, and Related Conditions: A Review of Reviews. Hayes, Inc. September 15, 2020.

Lin KY, Yang CC, Hsu CJ, et al. Intra-articular injection of platelet-rich plasma is superior to hyaluronic acid or saline solution in the treatment of mild to moderate knee osteoarthritis: A randomized, double-blind, triple-parallel, placebo-controlled clinical trial. *Arthroscopy*. 2019 Jan;35(1):106-117

Dai J, Jiang C, et al. Autologous platelet-rich plasma treatment for patients with diabetic foot ulcers: a meta-analysis of randomized studies. *J Diabetes Complications*. 2020 Aug;34(8):107611.

Bohlen HL, Schwartz ZE, et al. Platelet-Rich Plasma Is an Equal Alternative to Surgery in the Treatment of Type 1 Medial Epicondylitis. *Orthop J Sports Med*. 2020 Mar 25;8(3):2325967120908952.

Wallace P, Bezjian Wallace L, et al.. Effectiveness of Ultrasound-Guided Platelet-Rich Plasma Injections in Relieving Sacroiliac Joint Dysfunction. *Am J Phys Med Rehabil*. 2020 Aug;99(8):689-693.

Auriemma, M., et al. (2020). "Platelet-rich plasma for treatment of chronic proximal hamstring tendinopathy." *Regen Med*. 2020 Apr;15(4):1509-1518.

Yurtbay A, Say F, et al. Multiple platelet-rich plasma injections are superior to single PRP injections or saline in osteoarthritis of the knee: the 2-year results of a randomized, double-blind, placebo-controlled clinical trial. *Archives of Orthopaedic and Trauma Surgery*. <https://doi.org/10.1007/s00402-021-04230-2>

Hayes, Inc., Medical Technology Directory. Comparative Effectiveness Review of Platelet-Rich Plasma for Tendinopathies or Ligament Injuries of the Knee: A Review of Reviews. Lansdale, PA. Hayes, Inc. December 2017, Annual review May 2020.

Hayes, Inc., Medical Technology Directory. Comparative Effectiveness Review of Platelet-Rich Plasma for Rotator Cuff Repairs, Tendinopathies, and Related Conditions: A Review of Reviews. Lansdale, PA. Hayes, Inc. September 15, 2020

Hayes, Inc., Medical Technology Directory. Platelet-Rich Plasma for Treatment of Conditions of the Achilles Tendon and Plantar Fascia. Lansdale, PA: Hayes, Inc.; June 1, 2020

Centers for Medicare & Medicaid Services NCD 270.3 Blood-Derived Products for Chronic Non-Healing Wounds

Centers for Medicare & Medicaid Services. Novitas LCD L39068 Platelet Rich Plasma and A58808 Billing and Coding: Platelet Rich Plasma

Bennell KL, Paterson KL, Metcalf BR, et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis. The RESTORE randomized clinical trial. JAMA. 2021;326(20):2021-2030.

Kearney RS, Ji C, Warwick J, et al; ATM Trial Collaborators. Effect of platelet-rich plasma injection vs sham injection on tendon dysfunction in patients with chronic midportion Achilles tendinopathy: A randomized clinical trial. JAMA. 2021;326(2):137-144.

Dong Y, Zhang B, Yang Q, et.al. The effects of platelet-rich plasma injection in knee and hip osteoarthritis: a meta-analysis of randomized controlled trials. Clin Rheumatol 2021 Jan;40(1):263-277

This policy will be revised as necessary and reviewed no less than annually.

Devised: 06/2009

Revised: 6/10 (exclusion lang/refs), 9/16 (Title, Description, Exclusion); 11/16 (Add CMS CED provision); 3/18 (title change, add exclusion), 3/19 (add exclusion); 3/21 (add exclusions), 3/22 (revise CMS coverage position)

Reviewed: 6/11, 6/12, 6/13, 6/14, 5/15, 6/16, 8/17, 3/20, 3/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.